Biocept Inc. (BIOCQ)

Overview

Biocept, Inc. was a dedicated molecular oncology diagnostics company focused on the development and commercialization of novel clinical diagnostic assays for cancer. These diagnostics were designed to detect rare tumor cells and cell-free tumor DNA (ctDNA) in blood and cerebrospinal fluid (CSF), catering to the needs of patients across the United States. Aimed at providing key insights to healthcare providers, Biocept's assays facilitated the identification of oncogenic alterations. This enabled the tailoring of targeted therapies for cancer patients at various stages including diagnosis, progression, and to monitor resistance mechanisms. Incorporated in 1997 and headquartered in San Diego, California, Biocept, Inc. engaged in meaningful collaborations to enhance its offerings but unfortunately filed for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware on October 13, 2023.

Products and Services

Biocept, Inc. offered a comprehensive range of assays and testing services aimed at solid tumor and cerebrospinal fluid indications, with a focus on enhancing targeted therapy treatments and monitoring for cancer patients.

• Solid Tumor Indications: The company specialized in diagnostics for a variety of cancers including breast, non-small cell lung (NSCLC), gastric, colorectal, prostate, pancreaticobiliary, and ovarian cancer. These assays aimed to identify specific oncogenic alterations to guide the selection of targeted therapies.
• Cerebrospinal Fluid Tumor Cell and ctDNA/ctRNA Testing Services: Biocept provided advanced testing services for analyzing tumor cells and ctDNA/ctRNA in cerebrospinal fluid. This service supported medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, and pathologists in the diagnosis and treatment of brain and central nervous system cancers.
• Clinical Trial and Research Services: Beyond individual patient diagnostics, Biocept engaged with pharmaceutical companies, biopharmaceutical companies, and clinical research organizations. These services focused on leveraging Biocept's diagnostic assays for clinical trials and research, aiming to advance the understanding and treatment of cancer.
• Collaborations: Noteworthy partnerships included an initiative with CLEARED4 to develop a COVID-19 testing management system and a research collaboration with Protean BioDiagnostics. The latter focused on using Biocept’s Target Selector molecular assay to determine EGFR status in NSCLC patients, showcasing Biocept's commitment to improving diagnostic precision and targeted treatment strategies.